Reza Ganjali , Setare Nassiri , Narges Zamani , Zeinab Shaker-ardekani , Mohammad Elahimanesh , Nazanin Hosseinkhan , Mitra Nourbakhsh
{"title":"卵巢癌患者的肝癌源性生长因子和非编码RNA网络","authors":"Reza Ganjali , Setare Nassiri , Narges Zamani , Zeinab Shaker-ardekani , Mohammad Elahimanesh , Nazanin Hosseinkhan , Mitra Nourbakhsh","doi":"10.1016/j.bbrep.2025.102168","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Ovarian cancer (OC) remains the most lethal gynecologic malignancy due to late diagnosis and limited effective biomarkers. Hepatoma-derived growth factor (HDGF) has emerged as an oncogene implicated in tumor progression, yet its regulation and clinical potential in OC remains underexplored. Recent evidence suggests that long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) may modulate oncogenic pathways through competing endogenous RNA (ceRNA) networks.</div></div><div><h3>Methods and results</h3><div>Fifty ovarian cancer and fifty normal ovarian tissue samples were analyzed for HDGF, miR-345-5p, and LINC00839 expression using qRT-PCR. Bioinformatic tools were employed to predict RNA-RNA interactions and reconstruct a ceRNA network. Statistical analyses examined expression correlations and diagnostic performance via ROC curve. HDGF and LINC00839 were significantly upregulated, while miR-345-5p was downregulated in OC tissues (p < 0.001). HDGF expression correlated positively with LINC00839 (r = 0.70) and inversely with miR-345-5p (r = −0.58), suggesting a regulatory axis where LINC00839 sponges miR-345-5p to derepress HDGF. Elevated HDGF levels were associated with larger tumor size, advanced FIGO stage, and metastasis. ROC analysis revealed that HDGF serum level (AUC = 0.88) has promising diagnostic potential, albeit lower than CA-125 and HE4.</div></div><div><h3>Conclusion</h3><div>Our study highlights the LINC00839–miR-345-5p–HDGF axis as a key regulatory network in ovarian cancer. HDGF may serve as a clinically relevant biomarker for disease progression, while LINC00839 and miR-345-5p represent promising therapeutic targets. These findings provide a foundation for future investigations into ceRNA-based diagnostics and treatments in OC.</div></div>","PeriodicalId":8771,"journal":{"name":"Biochemistry and Biophysics Reports","volume":"43 ","pages":"Article 102168"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hepatoma-derived growth factor and non-coding RNA network in ovarian cancer patients\",\"authors\":\"Reza Ganjali , Setare Nassiri , Narges Zamani , Zeinab Shaker-ardekani , Mohammad Elahimanesh , Nazanin Hosseinkhan , Mitra Nourbakhsh\",\"doi\":\"10.1016/j.bbrep.2025.102168\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Ovarian cancer (OC) remains the most lethal gynecologic malignancy due to late diagnosis and limited effective biomarkers. Hepatoma-derived growth factor (HDGF) has emerged as an oncogene implicated in tumor progression, yet its regulation and clinical potential in OC remains underexplored. Recent evidence suggests that long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) may modulate oncogenic pathways through competing endogenous RNA (ceRNA) networks.</div></div><div><h3>Methods and results</h3><div>Fifty ovarian cancer and fifty normal ovarian tissue samples were analyzed for HDGF, miR-345-5p, and LINC00839 expression using qRT-PCR. Bioinformatic tools were employed to predict RNA-RNA interactions and reconstruct a ceRNA network. Statistical analyses examined expression correlations and diagnostic performance via ROC curve. HDGF and LINC00839 were significantly upregulated, while miR-345-5p was downregulated in OC tissues (p < 0.001). HDGF expression correlated positively with LINC00839 (r = 0.70) and inversely with miR-345-5p (r = −0.58), suggesting a regulatory axis where LINC00839 sponges miR-345-5p to derepress HDGF. Elevated HDGF levels were associated with larger tumor size, advanced FIGO stage, and metastasis. ROC analysis revealed that HDGF serum level (AUC = 0.88) has promising diagnostic potential, albeit lower than CA-125 and HE4.</div></div><div><h3>Conclusion</h3><div>Our study highlights the LINC00839–miR-345-5p–HDGF axis as a key regulatory network in ovarian cancer. HDGF may serve as a clinically relevant biomarker for disease progression, while LINC00839 and miR-345-5p represent promising therapeutic targets. These findings provide a foundation for future investigations into ceRNA-based diagnostics and treatments in OC.</div></div>\",\"PeriodicalId\":8771,\"journal\":{\"name\":\"Biochemistry and Biophysics Reports\",\"volume\":\"43 \",\"pages\":\"Article 102168\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemistry and Biophysics Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405580825002559\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry and Biophysics Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405580825002559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Hepatoma-derived growth factor and non-coding RNA network in ovarian cancer patients
Background
Ovarian cancer (OC) remains the most lethal gynecologic malignancy due to late diagnosis and limited effective biomarkers. Hepatoma-derived growth factor (HDGF) has emerged as an oncogene implicated in tumor progression, yet its regulation and clinical potential in OC remains underexplored. Recent evidence suggests that long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) may modulate oncogenic pathways through competing endogenous RNA (ceRNA) networks.
Methods and results
Fifty ovarian cancer and fifty normal ovarian tissue samples were analyzed for HDGF, miR-345-5p, and LINC00839 expression using qRT-PCR. Bioinformatic tools were employed to predict RNA-RNA interactions and reconstruct a ceRNA network. Statistical analyses examined expression correlations and diagnostic performance via ROC curve. HDGF and LINC00839 were significantly upregulated, while miR-345-5p was downregulated in OC tissues (p < 0.001). HDGF expression correlated positively with LINC00839 (r = 0.70) and inversely with miR-345-5p (r = −0.58), suggesting a regulatory axis where LINC00839 sponges miR-345-5p to derepress HDGF. Elevated HDGF levels were associated with larger tumor size, advanced FIGO stage, and metastasis. ROC analysis revealed that HDGF serum level (AUC = 0.88) has promising diagnostic potential, albeit lower than CA-125 and HE4.
Conclusion
Our study highlights the LINC00839–miR-345-5p–HDGF axis as a key regulatory network in ovarian cancer. HDGF may serve as a clinically relevant biomarker for disease progression, while LINC00839 and miR-345-5p represent promising therapeutic targets. These findings provide a foundation for future investigations into ceRNA-based diagnostics and treatments in OC.
期刊介绍:
Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.